45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
176,863
Insurances with rates
16
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 103958918-3940313 | 69866-1030-05 - autologous cultured chondrocytes 1 | $319,872 | $67,173 | — | — | 7 |
| 103958918-3940313 | 69866-1030-05 - autologous cultured chondrocytes 1 | $319,872 | $38,385 | — | — | 7 |
| 103958919-3940313 | 69866-1030-08 - autologous cultured chondrocytes 1 | $319,872 | $67,173 | — | — | 7 |
| 103958919-3940313 | 69866-1030-08 - autologous cultured chondrocytes 1 | $319,872 | $38,385 | — | — | 7 |
| 102534551-3940297 | 71336-1001-01 - givosiran 189 mg/mL Soln | $253,500 | $53,235 | — | — | 7 |
| 102534551-3940297 | 71336-1001-01 - givosiran 189 mg/mL Soln | $253,500 | $30,420 | — | — | 7 |
| 113173740-4084411 | S-REM-REP CVD MULT[OKAH] | $250,899 | $52,689 | — | — | 7 |
| 113173740-4084411 | S-REM-REP CVD MULT[OKAH] | $250,899 | $30,108 | — | — | 7 |
| 51905029-3938512 | 30237-8900-06 - sipuleucel-T - Susp | $247,856 | $52,050 | — | — | 7 |
| 51905029-3938512 | 30237-8900-06 - sipuleucel-T - Susp | $247,856 | $29,743 | — | — | 7 |
| 1279402-3940297 | 00003-2328-22 - ipilimumab Soln | $228,040 | $47,888 | — | — | 7 |
| 1279402-3940297 | 00003-2328-22 - ipilimumab Soln | $228,040 | $27,365 | — | — | 7 |
| 113173733-4084411 | S-INS-REP PACE-DEFIB[OKAH] | $218,806 | $45,949 | — | — | 7 |
| 113173733-4084411 | S-INS-REP PACE-DEFIB[OKAH] | $218,806 | $26,257 | — | — | 7 |
| 1286149-3940297 | 54396-0801-01 - pegloticase Soln | $185,845 | $39,027 | — | — | 7 |
| 1286149-3940297 | 54396-0801-01 - pegloticase Soln | $185,845 | $22,301 | — | — | 7 |
| 95367892-3940297 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $185,845 | $39,027 | — | — | 7 |
| 95367892-3940297 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $185,845 | $22,301 | — | — | 7 |
| 113173735-4084411 | S-REM-REP CVD DUAL[OKAH] | $179,170 | $37,626 | — | — | 7 |
| 113173735-4084411 | S-REM-REP CVD DUAL[OKAH] | $179,170 | $21,500 | — | — | 7 |
| 113173738-4084411 | S-INS PULSE GEN DUAL[OKAH] | $179,170 | $37,626 | — | — | 7 |
| 113173738-4084411 | S-INS PULSE GEN DUAL[OKAH] | $179,170 | $21,500 | — | — | 7 |
| 113173739-4084411 | S-REM-REP CVD SINGLE[OKAH] | $179,170 | $37,626 | — | — | 7 |
| 113173739-4084411 | S-REM-REP CVD SINGLE[OKAH] | $179,170 | $21,500 | — | — | 7 |
| 94990000-3940297 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $168,491 | $35,383 | — | — | 7 |
| 94990000-3940297 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $168,491 | $20,219 | — | — | 7 |
| 1282361-3940297 | 57665-0002-02 - pegaspargase 3750. Soln | $165,999 | $34,860 | — | — | 7 |
| 1282361-3940297 | 57665-0002-02 - pegaspargase 3750. Soln | $165,999 | $19,920 | — | — | 7 |
| 1282362-3940297 | 54482-0301-01 - pegaspargase 3750. Soln | $165,999 | $34,860 | — | — | 7 |
| 1282362-3940297 | 54482-0301-01 - pegaspargase 3750. Soln | $165,999 | $19,920 | — | — | 7 |
| 102525788-3940297 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $152,629 | $32,052 | — | — | 7 |
| 102525788-3940297 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $152,629 | $18,315 | — | — | 7 |
| 114297202-4084411 | DEV IMPELLA CP 14FRX04.7X75MM - 0048-0003[OKAH] | $143,113 | $30,054 | — | — | 7 |
| 114297202-4084411 | DEV IMPELLA CP 14FRX04.7X75MM - 0048-0003[OKAH] | $143,113 | $17,174 | — | — | 7 |
| 114770124-4084411 | ABIO-SET VNTRC IMPELLA 2.5 9F[OKAH] | $143,113 | $30,054 | — | — | 7 |
| 114770124-4084411 | ABIO-SET VNTRC IMPELLA 2.5 9F[OKAH] | $143,113 | $17,174 | — | — | 7 |
| 114782687-4084411 | ABIO-DSC-USE #2358147 PMP SET IMPELLA RP US 11F-US | $143,113 | $30,054 | — | — | 7 |
| 114782687-4084411 | ABIO-DSC-USE #2358147 PMP SET IMPELLA RP US 11F-US | $143,113 | $17,174 | — | — | 7 |
| 114804929-4084411 | BNDL IMPL W IMPLL PMP C9+ COMP - 4000021[OKAH] | $143,113 | $30,054 | — | — | 7 |
| 114804929-4084411 | BNDL IMPL W IMPLL PMP C9+ COMP - 4000021[OKAH] | $143,113 | $17,174 | — | — | 7 |
| 113173730-4084411 | S-TIB PER REV STN AT[OKAH] | $142,203 | $29,863 | — | — | 7 |
| 113173730-4084411 | S-TIB PER REV STN AT[OKAH] | $142,203 | $17,064 | — | — | 7 |
| 127538326-3938512 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $136,309 | $28,625 | — | — | 7 |
| 127538326-3938512 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $136,309 | $16,357 | — | — | 7 |
| 114770903-4084411 | ABBO-ANCH LD CNCH SPNL CORD STM 3.8[OKAH] | $132,734 | $27,874 | — | — | 7 |
| 114770903-4084411 | ABBO-ANCH LD CNCH SPNL CORD STM 3.8[OKAH] | $132,734 | $15,928 | — | — | 7 |
| 112954234-4084411 | IC-PRQ DE CR STNT AR[OKAH] | $129,819 | $27,262 | — | — | 7 |
| 112954234-4084411 | IC-PRQ DE CR STNT AR[OKAH] | $129,819 | $15,578 | — | — | 7 |
| 112954235-4084411 | IC-PRQ DE CR REV AMI[OKAH] | $129,819 | $27,262 | — | — | 7 |
| 112954235-4084411 | IC-PRQ DE CR REV AMI[OKAH] | $129,819 | $15,578 | — | — | 7 |
Showing top 50 of 176,863 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.